Jens Rosenau
Gastroenterology · Lexington, KYNPI 1245563469
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,560 of the $10,944 with a category attached, or 96.5%. Gilead accounts for 98.8% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2020 at $7,771 and has fallen 98.3% since, to $131 in 2025.
Across 9 payments — averaging $1216.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$11K
- Madrigal Pharmaceuticals$131
Across 13 payments — averaging $119,722 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$1.5M
- AbbVie$103K
What the payments were for
- Consulting fees$10,56096%
- Food & beverage$3844%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 8 | $10,813 |
| Madrigal Pharmaceuticals | 1 | $131 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZDIFFRA$131
How this compares
$10,944 in reported general payments places this provider in the 80th percentile of 207 gastroenterology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 41 | $133,394 |
| OcalivaObeticholic Acid | 11 | $91,533 |
| Ursodiol | 24 | $3,771 |
| Lactulose | 25 | $1,725 |
| Mercaptopurine | 12 | $1,468 |
| Nadolol | 25 | $973 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 38 | $499 |
| Azathioprine | 15 | $490 |
| Spironolactone | 16 | $419 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 24 | $376 |
| Carvedilol | 19 | $157 |
| Omeprazole | 12 | $65 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Lexington
- Terrence BarrettLexington$57K
- An-Yu ChenLexington$25K
- Kathleen MartinLexington$23K
- Gregory WoolfolkLexington$19K
- Matthew AshmunLexington$19K
- Deborah FlomenhoftLexington$18K
- Scott MerkleyLexington$18K
- James PezziLexington$15K
- Adalberto CastellanosLexington$13K
- June YongLexington$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.